LELauren Eggert

Lauren Eggert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lauren Eggert has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Con: clinical remission in asthma – not yet there

    by Lauren Eggert, Sarah Rhoads, Michael E. Wechsler, Praveen Akuthota

    The ideal definition of asthma remission should be practical, measurable and meaningful for both patients and physicians, while also representing true disease modification. Unfortunately, current proposals to define asthma remission fall short of this standard, not for lack of careful consideration, but due to the challenges presented by asthma, including but not limited to variability in symptom perception, intrinsic variability in lung function, seasonality and the impact of comorbidities. This article discusses obstacles and challenges to developing a widely adopted, consensus definition of asthma remission. We searched the literature for keywords including “asthma”, “remission” and “super-responder” and identified interventional trials in asthma that highlight the challenges inherent in defining asthma remission.


  • Open Access

    Low-dose naltrexone use for the management of post-acute sequelae of COVID-19

    by Hector Bonilla, Lu Tian, Vincent C. Marconi, Robert Shafer, Grace A. McComsey, Mitchel Miglis, Philip Yang, Andres Bonilla, Lauren Eggert, Linda N. Geng


  • Open Access

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic

    by H Bonilla, Tc Quach, A Tiwari, Ae Bonilla, M Miglis, P Yang, L Eggert, H Sharifi, A Horomanski, A Subramanian, et al.

    Background The global prevalence of PASC is estimated to be present in 0·43 and based on the WHO estimation of 470 million worldwide COVID-19 infections, corresponds to around 200 million people experiencing long COVID symptoms. Despite this, its clinical features are not well defined. Methods We collected retrospective data from 140 patients with PASC in a post-COVID-19 clinic on demographics, risk factors, illness severity (graded as one-mild to five-severe), functional status, and 29 symptoms and principal component symptoms cluster analysis. The Institute of Medicine (IOM) 2015 criteria were used to determine the ME/CFS phenotype. Findings The median age was 47 years, 59·0% were female; 49·3% White, 17·2% Hispanic, 14·9% Asian, and 6·7% Black. Only 12·7% required hospitalization. Seventy-two (53·5%) patients had no known comorbid conditions. Forty-five (33·9%) were significantly debilitated. The median duration of symptoms was 285·5 days, and the number of symptoms was 12. The most common symptoms were fatigue (86·5%), post-exertional malaise (82·8%), brain fog (81·2%), unrefreshing sleep (76·7%), and lethargy (74·6%). Forty-three percent fit the criteria for ME/CFS. Interpretations Most PASC patients evaluated at our clinic had no comorbid condition and were not hospitalized for acute COVID-19. One-third of patients experienced a severe decline in their functional status. About 43% had the ME/CFS subtype. Funding The study did not received funding.


  • Open Access

    Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19

    by Lauren E. Eggert, Ziyuan He, William Collins, Alexandra S. Lee, Gopal Dhondalay, Shirley Y. Jiang, Jessica Fitzpatrick, Theo T. Snow, Benjamin A. Pinsky, Maja Artandi, et al.

    Background: It is unclear whether asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS‐CoV‐2.Methods: All patients over 28 days old testing positive for SARS‐CoV‐2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub‐cohort was followed prospectively to evaluate long‐term COVID‐19 symptoms.Results: 168,190 patients underwent SARS‐CoV‐2 testing, and 6,976 (4.15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1.12 [95% CI 0.86, 1.45], p = .40). Among SARS‐CoV‐2‐positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared with non‐allergic asthma (OR 0.52 [0.28, 0.91], p = .026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID‐19 disease had lower eosinophil levels during hospitalization compared with patients with mild or asymptomatic disease, independent of asthma status (p = .0014). In a patient sub‐cohort followed longitudinally, asthmatics and non‐asthmatics had similar time to resolution of COVID‐19 symptoms, particularly lower respiratory symptoms.Conclusions: Asthma is not a risk factor for more severe COVID‐19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID‐19 compared with non‐allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with a more severe COVID‐19 disease trajectory. Recovery was similar among asthmatics and non‐asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms 3 months post‐infection.


  • Open Access

    Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19

    by Lauren Eggert, Ziyuan He, William Collins, Alexandra Lee, Gopal Dhondalay, Shirley Jiang, Jessica Fitzpatrick, Theo Snow, Benjamin Pinsky, Maja Artandi, et al.

    Background: It is unclear if asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS-CoV-2. Methods: All patients testing positive for SARS-CoV-2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub-cohort was followed prospectively to evaluate long-term COVID-19 symptoms. Results: 168,190 patients underwent SARS-CoV-2 testing, and 6,976 (4·15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1·12 [95% CI 0·86, 1·45], p=0·40). Among SARS-CoV-2 positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared to non-allergic asthma (OR 0·52 (0·28, 0·91), p=0·026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared to patients with mild or asymptomatic disease, independent of asthma status (p=0.0014). In a patient sub-cohort followed longitudinally, asthmatics and non-asthmatics had similar time to resolution of COVID-19 symptoms, particularly lower respiratory symptoms. Conclusions: Asthma is not a risk factor for more severe COVID-19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID-19 compared to non-allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with more severe COVID-19 disease trajectory. Recovery was similar among asthmatics and non-asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms three months post-infection.